close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

22.65 -0.45 (-1.95%)
Streaming Delayed Price Updated: 11:35 AM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) is a value investing candidate with strong fundamentals, low P/E ratios, robust financial health, high profitability, and impressive growth in the rare disease sector. 
Via Chartmill
How Is The Market Feeling About Catalyst Pharmaceuticals?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation
Catalyst Pharmaceuticals (CPRX) is a top GARP stock with strong growth, excellent profitability, and an attractive valuation, making it a compelling long-term investment. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate
Catalyst Pharmaceuticals (CPRX) excels in growth, profitability, and financial health, making it a top-quality stock for long-term investors according to the Caviar Cruise screen. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech
Catalyst Pharmaceuticals (CPRX) is a strong value stock with low P/E ratios, high profitability, zero debt, and impressive growth, offering a solid margin of safety. 
Via Chartmill
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For November 5, 2025
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Fundamentals and Technical Breakout Potential
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong EPS growth, high profitability, and a bullish technical breakout pattern. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong growth, solid earnings, and an affordable valuation for investors seeking value. 
Via Chartmill
What Does the Market Think About Catalyst Pharmaceuticals Inc?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) appears undervalued with strong financials: zero debt, high profitability, and robust growth, making it a compelling value investing candidate. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth
Discover Catalyst Pharmaceuticals (CPRX): a high-growth biotech stock with strong profitability, a solid balance sheet, and an attractive valuation. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals
Catalyst Pharmaceuticals (CPRX) offers strong growth, fair valuation, and solid financials, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Fits Louis Navellier’s Growth Investing Strategy with Strong Earnings Momentum and Rising Sales
Louis Navellier’s growth investing strategy highlights stocks like Catalyst Pharmaceuticals (CPRX), which shows strong earnings momentum, rising sales, and high profitability. CPRX meets key criteria,... 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential
Combine technical & fundamental analysis to spot growth stocks like Catalyst Pharmaceuticals (CPRX), showcasing strong financials & breakout potential. 
Via Chartmill
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals?
 
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential
Catalyst Pharmaceuticals (CPRX) is a value stock with strong fundamentals—low P/E, zero debt, high profitability, and robust growth, making it a standout in biotech. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth stocks. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender for Growth Investors
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors. 
Via Chartmill
Peering Into Catalyst Pharmaceuticals's Recent Short Interest
 
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a promising technical setup, making it a stock to watch. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Rare Biotech With Undervalued Potential
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks. 
Via Chartmill
Is Catalyst Pharmaceuticals Gaining or Losing Market Support?
 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Quarter
 
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A CANSLIM Candidate With Strong Growth Metrics
CATALYST PHARMACEUTICALS (CPRX) meets key CANSLIM criteria with strong earnings growth, high profitability, and market-leading relative strength. A debt-free balance sheet adds appeal. 
Via Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors
CATALYST PHARMACEUTICALS INC (CPRX) shows strong earnings growth, high profitability, and solid cash flow, making it a standout for growth investors. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and Value
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today